We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mirum Pharmaceuticals Inc | NASDAQ:MIRM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.48 | -1.82% | 25.91 | 25.50 | 26.70 | 26.77 | 25.59 | 26.54 | 271,526 | 22:30:00 |
1. Name and Address of Reporting Person * Flynn James E | 2. Issuer Name and Ticker or Trading Symbol Mirum Pharmaceuticals, Inc. [ MIRM ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) __X__ Other (specify below) * Possible Member of 10% Group |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 7/2/2021 | S | 10599 | D | $17.011 (1) | 155401 | I | Through Deerfield Special Situations Fund, L.P. (4)(5) | ||
Common Stock | 7/6/2021 | S | 49239 | D | $16.195 (2) | 106162 | I | Through Deerfield Special Situations Fund, L.P. (4)(5) | ||
Common Stock | 7/7/2021 | S | 6837 | D | $15.869 (3) | 99325 | I | Through Deerfield Special Situations Fund, L.P. (4)(5) | ||
Common Stock | 1558456 | I | Through Deerfield Healthcare Innovations Fund, L.P. (4)(5) | |||||||
Common Stock | 1724456 | I | Through Deerfield Private Design Fund IV, L.P. (4)(5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Remarks: Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn. |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Flynn James E 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK, NY 10010 | X | * Possible Member of 10% Group | |||
Deerfield Mgmt HIF, L.P. 345 PARK AVENUE SOUTH, 12TH FLOOR 37TH FLOOR NEW YORK, NY 10010 | X | * Possible Member of 10% Group | |||
Deerfield Mgmt IV, L.P. 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK, NY 10010 | X | * Possible Member of 10% Group | |||
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK, NY 10010 | X | * Possible Member of 10% Group | |||
Deerfield Private Design Fund IV, L.P. 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK, NY 10010 | X | * Possible Member of 10% Group | |||
Deerfield Healthcare Innovations Fund, L.P. 345 PARK AVENUE SOUTH, 12TH FLOOR 37TH FLOOR NEW YORK, NY 10010 | X | * Possible Member of 10% Group | |||
Deerfield Mgmt L.P. 345 PARK AVENUE SOUTH, 12TH FLOOR 37TH FLOOR NEW YORK, NY 10010 | X | * Possible Member of 10% Group | |||
Deerfield Special Situations Fund, L.P. 345 PARK AVENUE SOUTH, 12TH FLOOR 37TH FLOOR NEW YORK, NY 10010 | X | * Possible Member of 10% Group |
Signatures | ||
/s/ Jonathan Isler, Attorney-in-Fact | 7/7/2021 | |
**Signature of Reporting Person | Date |
1 Year Mirum Pharmaceuticals Chart |
1 Month Mirum Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions